Ankylosing Spondylitis
📧 Sign up to get email alerts when something new happens for Ankylosing Spondylitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-10-07FDA Approved: PIROXICAM — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for piroxicam by Micro Labs Limited, adding or updating a generic piroxicam product.
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs [Phase 4]
A phase 4 clinical trial evaluating a treat-to-target strategy in ankylosing spondylitis using etanercept and conventional synthetic DMARDs.
-
FDA approval · 2019-09-24FDA Approved: SIMPONI — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for SIMPONI (golimumab) submitted by Janssen Biotech, Inc. The approval updates the drug's label…
-
CLINICAL_TRIALS trial_result · 2019-09-09Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis [Phase 3]
A Phase 3 trial evaluating efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis has completed with res…
-
CLINICAL_TRIALS trial_result · 2019-08-22Clinical Trial Update: Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS [Phase 4]
Phase 4 trial update on sequential use of Yisaipu and DMARDs for treating mild-to-moderate ankylosing spondylitis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-08-07FDA Approved: CELECOXIB — Original Application (AiPing Pharmaceutical, Inc.)
The FDA approved AiPing Pharmaceutical, Inc.'s original ANDA for celecoxib, establishing a generic version of the COX-2 inhibitor. The appro…
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: Extension in AS: Sustainability of Benefits, Safety and Tolerability [Phase 3]
Phase 3 extension study update on sustainability of benefits, safety, and tolerability for AS (ankylosing spondylitis).
-
FDA approval · 2019-07-25FDA Approved: CELECOXIB — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for celecoxib from Apotex Corp., granting approval for a generic version of the product.
-
FDA approval · 2019-07-25FDA Approved: CELECOXIB — Supplemental Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's supplemental application for Celecoxib (generic Celecoxib), confirming the generic's approval. Celec…
-
FDA approval · 2019-07-23FDA Approved: HADLIMA — Original Application (Organon LLC)
FDA approves Hadlima (adalimumab-bwwd) from Organon as a biosimilar to Humira under the original application BLA761059. It is indicated for …
-
CLINICAL_TRIALS research · 2019-07-05Clinical Trial Update: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
A completed registry study evaluating HUMIRA (adalimumab) in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with res…
-
CLINICAL_TRIALS trial_result · 2019-06-21Clinical Trial Update: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta [Phase 1]
Phase 1 postmarketing transfer study evaluating Cimzia (certolizumab pegol) from mother to infant via placenta has completed with results po…
-
FDA approval · 2019-06-13FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental application for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS) [Phase 2]
Phase 2 dose-finding study of risankizumab (BI 655066) in ankylosing spondylitis completed with results posted in 2019.
-
EMA safety_alert · 2019-05-17Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs
The EMA announced restrictions on the use of Xeljanz (tofacitinib) while it reviews the risk of blood clots in the lungs, indicating potenti…
-
CLINICAL_TRIALS trial_result · 2019-05-17Clinical Trial Update: The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patients [Phase 2]
Phase 2 clinical trial investigating the effects of nanocurcumin on regulatory T and Th17 cell responses in patients with Ankylosing Spondyl…
-
FDA approval · 2019-05-06FDA Approved: DICLOFENAC SODIUM — Original Application (Harris Teeter)
FDA approved Harris Teeter's diclofenac sodium as a generic under an original ANDA.
-
CLINICAL_TRIALS trial_result · 2019-04-30Clinical Trial Update: A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis [Phase 4]
Phase 4 randomized trial evaluating Fengshigutong Capsule for ankylosing spondylitis.
-
CLINICAL_TRIALS trial_result · 2019-04-10Clinical Trial Update: 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis [Phase 3]
A Phase 3 clinical trial update reports 16-week efficacy and 2-year safety, tolerability, and efficacy data for secukinumab in participants …
-
CLINICAL_TRIALS trial_result · 2019-04-03Clinical Trial Update: Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Clinical trial update for ankylosing spondylitis study; trial completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-03-13Clinical Trial Update: An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis [Phase 3]
Phase 3 trial of ustekinumab in active nonradiographic axial spondyloarthritis was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2019-03-12Clinical Trial Update: A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis [Phase 3]
Phase 3 trial evaluating ENIA11 for ankylosing spondylitis has been terminated.
-
EMA withdrawal · 2019-03-06EMA Withdrawn: Cyltezo (adalimumab) — Boehringer Ingelheim International GmbH
The EMA withdrew Cyltezo (adalimumab) from Boehringer Ingelheim International GmbH, affecting multiple indications including hidradenitis su…
-
EMA withdrawal · 2019-03-05EMA Withdrawn: Solymbic (adalimumab) — Amgen Europe B.V.
Solymbic (adalimumab) has been withdrawn from the market by Amgen Europe B.V.
-
CLINICAL_TRIALS trial_result · 2019-01-28Clinical Trial Update: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
This clinical trial update reports on patient adherence attitudes toward scheduled adalimumab maintenance therapy across multiple inflammato…